Researchers have found a way of identifying which ovarian cancer patients are likely to respond well to a new anti-cancer drug called rucaparib.
Nov 20, 2014
0
0
Patient prognosis and treatment response prediction are key factors in treating ovarian cancer, which is characterized by the lowest survival rate among gynecological cancers. Consequently, there is strong demand for a more ...
Apr 15, 2024
0
0
Targeted therapy in early stages of breast cancer can pave the way for a notable higher success rate, shows a study from the University of Bergen, Norway (UiB).
Apr 20, 2021
0
5
A research team led by Professor Ying Wai Chan from the School of Biological Sciences at The University of Hong Kong (HKU) has made a significant breakthrough in understanding how cancer cells develop resistance to a class ...
Jul 31, 2024
0
22
Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors, UCLA researchers have shown for the first time.
Nov 12, 2013
0
0
Advanced estrogen receptor-positive (ER+) breast cancer can be especially difficult to treat. A new study by researchers at Dartmouth Cancer Center led by Todd W. Miller, Ph.D., shows promise in using a combination of estrogen ...
Jul 13, 2023
0
6
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented ...
Oct 22, 2013
0
0
Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers—ATR inhibitor elimusertib and PARP inhibitor AZD5305—are safe and clinically beneficial in treating ...
Apr 11, 2022
0
4
(HealthDay)—Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a significant role in survival for ovarian cancer, according to ...
Mar 27, 2018
0
4
St. Jude Children's Research Hospital scientists report the first successful treatment of a pediatric patient with high-risk refractory neuroblastoma using a targeted therapy guided by clinical genomics.
Aug 15, 2024
0
8
